Evaluation of a Vaccine Chatbot on HPV Vaccine Confidence and Hesitancy (NCT07200570) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Evaluation of a Vaccine Chatbot on HPV Vaccine Confidence and Hesitancy
1,800 participantsStarted 2026-08
Plain-language summary
The goal of this clinical trial is to learn if a chatbot powered by artificial intelligence works to improve HPV vaccination among females aged 15 to 45 in China. A randomized controlled trial and implementation science study will be conducted targeting females as participants. The main questions it aims to answer are:
1. Does the vaccine chatbot influence women's confidence, literacy, hesitancy, and uptake of the HPV vaccine.
2. What are the public acceptance of chatbot and the facilitators and barriers to its implementation in a real-world setting.
Researchers will compare a group of women who use the chatbot with a group who do not use it to see if the chatbot is effective at helping women feel confident and willing to get vaccinated against HPV.
Participants will:
1. Be recruited and randomly allocated into one of two groups. One group will be invited to use the HPV vaccine chatbot and the other group will not get access to the vaccine chatbot until the end of the trial.
2. Complete a questionnaire survey on their confidence, literacy, and hesitancy on the HPV vaccine.
3. Have their vaccination status checked at the end of trial.
Who can participate
Age range
15 Years – 45 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Female, aged 15 to 45 years, inclusive.
* Not previously vaccinated against HPV.
* Reports no contraindications to HPV vaccination.
* Has no mental, visual, or reading impairments that would preclude cooperation with study activities.
* Is willing and able to provide informed consent.
Exclusion Criteria:
* Male.
* Age under 15 or over 45 years.
* Has a history of prior HPV vaccination.
* Has a known contraindication to HPV vaccination.
* Unable to comply with study procedures.
* Is unwilling or unable to provide informed consent.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
HPV Vaccine Uptake
Timeframe: Three months after participant randomization allocation